Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14391MR)

This product GTTS-WQ14391MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14391MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7165MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ4564MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ8045MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ3588MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ11017MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ8789MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ7145MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ5095MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW